Dupont Vincent, Xhaard Constance, Behm-Ansmant Isabelle, Bresso Emmanuel, Thuillier Quentin, Branlant Christiane, Lopez-Sublet Marilucy, Deleuze Jean-François, Zannad Faiez, Girerd Nicolas, Rossignol Patrick
Department of Nephrology, University hospital of Reims, Reims, France.
FCRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists ).
Clin Kidney J. 2024 Jul 18;17(8):sfae224. doi: 10.1093/ckj/sfae224. eCollection 2024 Aug.
Identifying the biomarkers associated with new-onset glomerular filtration rate (GFR) decrease in an initially healthy population could offer a better understanding of kidney function decline and help improving patient management.
Here we described the proteomic and transcriptomic footprints associated with new-onset kidney function decline in an initially healthy and well-characterized population with a 20-year follow-up. This study was based on 1087 individuals from the familial longitudinal Suivi Temporaire Annuel Non-Invasif de la Santé des Lorrains Assurés Sociaux (STANISLAS) cohort who attended both visit 1 (from 1993 to 1995) and visit 4 (from 2011 to 2016). New-onset kidney function decline was approached both in quantitative (GFR slope for each individual) and qualitative (defined as a decrease in GFR of >15 ml/min/1.7 m) ways. We analysed associations of 445 proteins measured both at visit 1 and visit 4 using Olink Proseek panels and 119 765 genes expressions measured at visit 4 with GFR decline. Associations were assessed using multivariable models. The Bonferroni correction was applied.
We found several proteins (including PLC, placental growth factor (PGF), members of the tumour necrosis factor receptor superfamily), genes (including ), and a newly discovered miRNA-mRNA pair (MIR1205-DNAJC6) to be independently associated with new-onset kidney function decline. Complex network analysis highlighted both extracellular matrix and cardiovascular remodelling (since visit 1) as well as inflammation (at visit 4) as key features of early GFR decrease.
These findings lay the foundation to further assess whether the proteins and genes herein identified may represent potential biomarkers or therapeutic targets to prevent renal function impairment.
在初始健康人群中识别与新发肾小球滤过率(GFR)下降相关的生物标志物,有助于更好地理解肾功能衰退,并有助于改善患者管理。
在此,我们描述了在一个经过20年随访的初始健康且特征明确的人群中,与新发肾功能衰退相关的蛋白质组学和转录组学特征。本研究基于来自家族性纵向非侵入性洛林参保人年度健康随访(STANISLAS)队列的1087名个体,他们参加了第1次随访(1993年至1995年)和第4次随访(2011年至2016年)。新发肾功能衰退通过定量(每个个体的GFR斜率)和定性(定义为GFR下降>15 ml/min/1.7 m²)两种方式进行评估。我们使用Olink Proseek检测板分析了在第1次和第4次随访时测量的445种蛋白质以及在第4次随访时测量的119765个基因表达与GFR下降之间的关联。使用多变量模型评估关联。应用了Bonferroni校正。
我们发现几种蛋白质(包括磷脂酶C、胎盘生长因子(PGF)、肿瘤坏死因子受体超家族成员)、基因(包括 )以及新发现的miRNA-mRNA对(MIR1205-DNAJC6)与新发肾功能衰退独立相关。复杂网络分析突出了细胞外基质和心血管重塑(自第1次随访起)以及炎症(在第4次随访时)是早期GFR下降的关键特征。
这些发现为进一步评估本文鉴定的蛋白质和基因是否可能代表预防肾功能损害的潜在生物标志物或治疗靶点奠定了基础。